Cargando…

Maraviroc Intensification Improves Endothelial Function in Abacavir-Treated Patients, an Open-Label Randomized Cross-Over Pilot Study

BACKGROUND: The increased risk of abacavir in cardiovascular disease (CVD) in HIV-infected patients is still being debated. Maraviroc, a CCR5 blocker, has been shown to decrease immune activation and monocyte infiltration in atherosclerotic plaques in murine experiments. Therefore, we examined the e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krikke, Maaike, Tesselaar, Kiki, Arends, Joop E., Drylewicz, Julia, Otto, Sigrid A., van Lelyveld, Steven F. L., Visseren, Frank J. L., Hoepelman, Andy I. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019971/ https://www.ncbi.nlm.nih.gov/pubmed/27300170 http://dx.doi.org/10.1007/s40121-016-0115-0

Ejemplares similares

Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial
por: van Lelyveld, Steven F. L., et al.
Publicado: (2015)

Effect of Maraviroc Intensification on HIV-1-Specific T Cell Immunity in Recently HIV-1-Infected Individuals
por: Kawana-Tachikawa, Ai, et al.
Publicado: (2014)

Maraviroc intensification for HIV-1-positive immunological non-responders (INRs) despite virological suppression during HAART
por: Rusconi, S, et al.
Publicado: (2010)

Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial
por: Rusconi, Stefano, et al.
Publicado: (2013)

Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification
por: Ananworanich, Jintanat, et al.
Publicado: (2015)

The balancing perspective of hard-to-reach hepatitis C patients who were lost to follow-up: A qualitative study
por: Kracht, Patricia A. M., et al.
Publicado: (2020)

Reconciling Longitudinal Naive T-Cell and TREC Dynamics during HIV-1 Infection
por: Drylewicz, Julia, et al.
Publicado: (2016)

Maraviroc Intensification Modulates Atherosclerotic Progression in HIV-Suppressed Patients at High Cardiovascular Risk. A Randomized, Crossover Pilot Study
por: Francisci, Daniela, et al.
Publicado: (2019)

Impact of antiretroviral therapy intensification with C-C motif chemokine receptor 5 antagonist maraviroc on HIV-associated neurocognitive impairment
por: Shikuma, Cecilia M., et al.
Publicado: (2023)

Impact of Aging, Cytomegalovirus Infection, and Long-Term Treatment for Human Immunodeficiency Virus on CD8(+) T-Cell Subsets
por: Veel, Ellen, et al.
Publicado: (2018)

Reconciling Estimates of Cell Proliferation from Stable Isotope Labeling Experiments
por: Ahmed, Raya, et al.
Publicado: (2015)

Abacavir forms novel cross-linking abacavir protein adducts in patients
por: Meng, Xiaoli, et al.
Publicado: (2014)

Estimating regional prevalence of chronic hepatitis C with a capture-recapture analysis
por: Kracht, Patricia A. M., et al.
Publicado: (2021)

Failure of combined antiretroviral therapy intensification with maraviroc and raltegravir in chronically HIV-1 infected patients to reduce the viral reservoir: the IntensHIV randomized trial
por: Lafeuillade, Alain, et al.
Publicado: (2014)

Maraviroc in the treatment of HIV infection
por: Ray, Neelanjana
Publicado: (2009)

A Review of Non-Alcoholic Fatty Liver Disease in HIV-Infected Patients: The Next Big Thing?
por: van Welzen, Berend J., et al.
Publicado: (2019)

Effect of abacavir on sustained virologic response to HCV treatment in HIV/HCV co-infected patients, Cohere in Eurocoord
por: Smit, Colette, et al.
Publicado: (2015)

Cell-density independent increased lymphocyte production and loss rates post-autologous HSCT
por: Baliu-Piqué, Mariona, et al.
Publicado: (2021)

The Effects of Boceprevir and Telaprevir on the Pharmacokinetics of Maraviroc: An Open-Label, Fixed-Sequence Study in Healthy Volunteers
por: Vourvahis, Manoli, et al.
Publicado: (2014)

Use of maraviroc in patients with undetectable viral load: efficacy, tolerance and predictors of viral response in MARAVIROC-cohort study
por: Jesús Pérez Elías, María, et al.
Publicado: (2014)

Abacavir-induced liver toxicity
por: Pezzani, Maria Diletta, et al.
Publicado: (2016)

Short Lifespans of Memory T-cells in Bone Marrow, Blood, and Lymph Nodes Suggest That T-cell Memory Is Maintained by Continuous Self-Renewal of Recirculating Cells
por: Baliu-Piqué, Mariona, et al.
Publicado: (2018)

Dynamics of Recent Thymic Emigrants in Young Adult Mice
por: van Hoeven, Vera, et al.
Publicado: (2017)

Maraviroc: the evidence for its potential in the management of HIV
por: Profit, Louise
Publicado: (2007)

Residual Viremia Is Preceding Viral Blips and Persistent Low-Level Viremia in Treated HIV-1 Patients
por: Hofstra, Laura Marije, et al.
Publicado: (2014)

Lymphocyte maintenance during healthy aging requires no substantial alterations in cellular turnover
por: Westera, Liset, et al.
Publicado: (2015)

Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients
por: Gonzalez-Serna, Alejandro, et al.
Publicado: (2016)

Abacavir methanol 2.5-solvate
por: Pham, Phuong-Truc T.
Publicado: (2009)

Alopecia Areata Associated with Abacavir Therapy
por: Kim, Hee-Sung, et al.
Publicado: (2014)

Quantification of T-cell dynamics during latent cytomegalovirus infection in humans
por: van den Berg, Sara P. H., et al.
Publicado: (2021)

Diazabicyclo analogues of maraviroc: synthesis, modeling, NMR studies and antiviral activity
por: Legnani, L., et al.
Publicado: (2016)

Hazardous thunderstorm intensification over Lake Victoria
por: Thiery, Wim, et al.
Publicado: (2016)

Progressive multifocal leukoencephalopathy and black fungus in a patient with rheumatoid arthritis without severe lymphocytopenia
por: de Regt, Marieke J. A., et al.
Publicado: (2016)

Improvement of endothelial function after switching previously treated HIV-infected patients to an NRTI-sparing bitherapy with maraviroc
por: Bernal, Enrique, et al.
Publicado: (2014)

Implications of maraviroc and/or rapamycin in a mouse model of fragility
por: Pérez-Martínez, Laura, et al.
Publicado: (2020)

Relaxation Effect of Abacavir on Rat Basilar Arteries
por: Li, Rachel Wai Sum, et al.
Publicado: (2015)

Structural Elements Recognized by Abacavir-Induced T Cells
por: Yerly, Daniel, et al.
Publicado: (2017)

Abacavir use is associated with increased prothrombin conversion
por: Yan, Qiuting, et al.
Publicado: (2023)

Use of lipid-lowering therapy after ischaemic stroke and expected benefit from intensification of treatment
por: Gynnild, Mari Nordbø, et al.
Publicado: (2022)

AOP-Based Transformation of Abacavir in Different Environments: Evolution Profile of Descyclopropyl-Abacavir and In Silico Toxicity Assessment of the Main Transformation Products
por: Evgenidou, Eleni, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8jld6ep1bkuk064ld7mv2f6jgv